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Antiretroviral drug concentrations in semen of
HIV-1 infected men
Stephen Taylor, Arlene S Pereira
Because semen is a major vehicle for the sexual transmission of HIV-1, control of viral replica-
tion within the sanctuary of the male genital tract should be a goal of antiretroviral therapy. Local
immune responses, virus specific factors, and the degree of viral and cellular traYcking all
appear to be important in controlling viral replication and evolution. However, the most impor-
tant factor influencing viral replication and evolution within the male genital tract may be the
disposition of antiretroviral agents into genital tissues and fluids. This review proposes possible
mechanisms of antiretroviral distribution into the male genital tract by using other sanctuary
barriers; such as the placenta, renal tubules, and blood-brain barrier; as models. In addition, this
review summarises recent clinical studies regarding the disposition of currently available
antiretroviral drugs into the seminal plasma and discusses some of the diYculties in interpreting
drug concentration in the genital tract.
(Sex Transm Inf 2001;77:4–11)
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HIV-1 spreads primarily from HIV-1 infected
men to their sexual partners via contact with
infected semen.1 2 Evidence is accumulating
that the genital tract may represent a separate
compartment or “sanctuary site” in which HIV
may be subject to unique selective pressures.3 4
Therefore, it is important that factors influenc-
ing viral replication and evolution within the
male genital tract be fully understood.
Recently, the positive eVects of highly active
antiviral therapy (HAART) and treatment of
concurrent sexually transmitted diseases on
seminal shedding have been described.5–9
Whether this will be reflected by a reduced
sexual transmission of HIV in developed coun-
tries has yet to be proved. However, there are
discouraging reports of drug resistant mutants
within semen,9–11 and sexual transmission of
drug resistant HIV-1.12–14
An antiviral drug concentration within the
male genital tract is one important factor influ-
encing viral replication and the development of
resistant virus. In this article, we review the
basic pharmacokinetic mechanisms that deter-
mine the disposition of antiviral drugs into the
male genital tract and summarise the current
data on antiviral drug concentrations in the
semen of HIV-1 infected men
This review addresses the following topics:
(1) Components and properties of seminal
plasma
(2) Basic principles of drug accumulation and
distribution
(3) Passive distribution of antiretrovirals into
the male genital tract
(4) Distribution mechanisms of antiretroviral
agents into other sanctuary sites
(5) Drug disposition of currently available
antiretrovirals into semen
(6) Factors limiting interpretation of drug
concentrations in seminal plasma.
Seminal plasma
Seminal plasma is the cell-free fraction of
ejaculate. It contains contributions from the
testis, epididymis, prostate, seminal vesicles,
and urethral (Littre’s) and bulbourethral
(Cowper’s) glands. Thus, seminal plasma
represents a conglomerate of all secretory
organs within the male genital tract, and is a
common surrogate for studying the male geni-
tal tract. The average ejaculate is slightly alka-
line (pH 7.2–7.6) with an average volume of
2.5–5 ml.15 16 Sixty per cent (v/v) of the
ejaculate originates from the seminal vesicles
and 30% from the prostate. The remainder is a
combination of secretions from the urethral
and bulbourethral glands, testis, and epidi-
dymis.17 A split, or fractionated, ejaculate can
be used to study drug penetration into the male
genital tract through specific tissues and
glands.
The fraction of semen from the testis/
epididymis is sperm rich with a protein poor
fluid. Prostatic fluid is protein rich, has a pH of
6.6, and is the main source of seminal acid
phosphatase, citric acid, and zinc. Fluid from
the seminal vesicles is also protein rich, but is
more alkaline (pH 7.8) and is the main source
of seminal fructose and prostaglandins.16–18
Some seminal proteins, like seminin, are
proteases. These proteases degrade other semi-
nal proteins and may release any bound or
associated drugs.
It is important to remember seminal plasma
is a dynamic entity, with nutrients for sperm
development entering and waste materials
leaving. Thus, its composition can vary be-
tween diVerent individuals and between diVer-
ent ejaculates from the same individual. In
addition, it is important to remember ejacula-
tion in essence is a process of elimination. Fre-
quent ejaculation can temporarily deplete the



































macokinetics of antiretrovirals into seminal
plasma.
Drug disposition and accumulation
Once entering the blood stream, drugs travel
throughout the body via the systemic circula-
tion. Leaving the circulation and entering other
compartments is drug disposition. In general,
disposition from the capillary lumen to the
extravascular compartments occurs by diVu-
sion and/or active transport. In many organs,
diVusion occurs through and between capillary
endothelial cells. However, tight junctions exist
between testicular (and perhaps prostatic and
vesicular) endothelial cells. These junctions
prevent diVusion between endothelial cells.15
Drug accumulation, or concentration, in a
tissue or biological fluid occurs when the influx
of a drug is greater than its eZux. Because the
rate of diVusion decreases as the concentration
gradient decreases diVusion alone cannot lead
to accumulation. However, concentration gra-
dients do not govern the rate of active
transport. Thus, active transport can play a
part in accumulation. Drug sequestration is
also responsible for accumulation. Sequestra-
tion involves either drug ionisation or drug
binding to proteins and other macromolecules,
preventing eZux by diVusion and/or trans-
port.15
Antiretroviral diVusion into seminal
plasma
DiVusion can be either simple (non-mediated)
or carrier mediated. Carrier mediated diVusion
has some characteristics that are similar to
active transport—specificity, saturation kinet-
ics, and susceptibility to competitive inhibition.
Simple diVusion requires no transporters; thus,
it is non-specific, non-saturable, and not
susceptible to competitive inhibition. A drug
will only diVuse in the direction that reduces its
concentration gradient. Thus, at equilibrium,
concentration of diVusible drug on both sides
of the membrane will be equal.19 The major
physiochemical determinants of diVusion are
degree of ionisation, lipid solubility, and size.20
Frick’s law of diVusion mathematically de-
scribes how these variables determine the rate
of simple diVusion.19 20
LIPID SOLUBILITY
Endothelial cells are essentially lipid mem-
branes, and Frick’s law applies to both. The
partition coeYcient (K) describes the equilib-
rium distribution of a drug between organic
and aqueous phases in a two layer system. In
short, the coeYcient predicts the likelihood of a
drug diVusing across a membrane, or endothe-
lial cell.19 There is a hypothetical bell-shaped
relation between the ability of a drug to diVuse
across a membrane and its lipid solubility. Only
drugs with some degree of lipophilicity and
hydrophobicity should partition into and out of
biological membranes.21 Figure 1 describes the
eVects of lipid solubility on membrane diVu-
sion.
ANTIRETROVIRALS AND LIPOPHILICITY
Glynn and Yazdanian21 experimentally deter-
mined the partition coeYcient between octanol
and phosphate buVered saline (pH 7.4) of
various antiretrovirals, including didanosine
(ddI), stavudine (d4T), zalcitabine (ddC),
zidovudine (ZDV), nevirapine (NVP), indina-
vir (IDV), saquinavir (SQV), and amprenavir
(APV). They also studied the diVusion, or per-
meability, of these antiretrovirals across bovine
brain endothelial cells. As predicted, they
found a bell-shaped relation between lipid
solubility and drug diVusion/permeability. Ne-
virapine is moderately lipophilic and most per-
meable. The nucleosides, although similar to
nevirapine in size and molecular weight, are
more hydrophilic and less permeable. The pro-
tease inhibitors (PIs) are more lipophilic than
the other antiretrovirals in the study. Amprena-
vir is both slightly less lipophilic and more per-
meable than the other PIs studied. Table w1
(on the STI website) describes the lipid
solubility of select antiretrovirals.
IONISATION
The degree of ionisation is dependent on the
pKa of the drug and the pH of its environ-
ment.22 23 Because the pH on one side of a
membrane can diVer from the pH on the other,
ionisation may diVer between membrane sepa-
rated compartments. Because ionisation in-
creases hydrophilicity, only non-ionised drugs
diVuse through biological membranes. Ion
trapping (or sequestering) occurs when ionisa-
tion diVers on the two sides of the membrane.
At equilibrium, non-ionised drug concentra-
tion on each side of the membrane will be equal
while total drug concentration (ionised and
non-ionised) on the two sides can be unequal24
(fig 1). Modified versions of the Henderson-
Hasselbalch equation predict the ratio, at equi-
librium, between drug concentrations in two
diVerent solutions of known pH.22 23
ANTIRETROVIRALS AND IONISATION
Ion trapping is an important concept, since the
pH of blood plasma (7.4) is almost a log diVer-
ent from the pH of prostatic fluid (6.6). Thus,
weak bases may accumulate in prostatic fluid.
In fact, Henry et al25 suggested ion trapping as
the mechanism for zidovudine accumulation
(pKa 9.68) in seminal plasma. The pH
gradient between blood plasma and vesicular
fluid (pH 7.4 versus pH 7.8) is less dramatic;
thus, it is unlikely that there will be any signifi-
cant ion trapping for any drug in the seminal
vesicles. Table w1 (on website) contains pKa
values of selected antiretrovirals.
PROTEIN BINDING—SIZE
According to Frick’s law, small drugs diVuse
across membranes faster than large drugs. The
eVective size of a drug increases if it binds to
macromolecules, including DNA and proteins.
Thus, when a drug is bound its diVusion rate
becomes so slow that diVusion is negligible and
only free (unbound) drug appreciably diVuses
across biological membranes.26 Such binding is
usually reversible with on/oV rates and associ-
ation constants. Drug accumulation can occur
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Figure 1 Overview of drug distribution between the systemic circulation and the male genital tract. Drug distribution is the result of drug deposition by
either (A) passive diVusion or (B) mediated transport. The partition coeYcient, size, and concentration of the drug determine the rate of diVusion.
Mediated transport requires recognition between the transporter and drug and energy to move the drug against its concentration gradient. Mediated
transport, and not diVusion, is saturable and susceptible to competitive inhibition. Both (C) sequestration and (D) accumulation lead to concentration of
drug in the systemic circulation and male genital tract, respectively. It is likely that protein binding, ion trapping, and active mediated transport have a role
in sequestration and accumulation. A combination of passive diVusion, protein binding, ion trapping, and active transport are all likely mediators of drug
disposition into the male genital tract. At the genital tract barrier, organic anion and organic cation transporters may transport nucleoside analogues and
p-glycoprotein may transport protease inhibitors, as they do at other sanctuary barriers. By studying the mechanism of drug disposition at other barriers,
scientists may understand the process of drug disposition into the male genital tract.
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when the amount of drug binding diVers on
each side of the membrane. When binding dif-
fers, total drug concentration on each side of
the membrane will be unequal while unbound
drug concentration will be equal, at equilib-
rium (fig 1). It has been hypothesised that
greater than 80% binding is required to aVect
drug disposition.26–29
ANTIRETROVIRALS AND PLASMA PROTEIN BINDING
Protein binding also aVects the diVusion of
antiretrovirals across membranes, including
into target cells. Because current antiretrovirals
only act within cells, it has been hypothesised
that by studying the eVects of extracellular
proteins on intracellular antiviral activity one
can indirectly determine the eVects of protein
binding on drug distribution.
As organic bases, protease inhibitors are
attracted to á1-acid glycoprotein (AAG). Zhang
et al30 studied the eVect of AAG on the antiviral
eYcacy of select antiretrovirals: SQV, ritonavir
(RTV), IDV, nelfinavir (NFV), APV, and ZDV.
As predicted, increasing AAG concentration
causes a decrease in PI activity. Addition of
AAG to PIs aVects IDV activity the least; NFV,
RTV, APV the most; and has a moderate eVect
on SQV. This corresponds to the degree of
PI-AAG binding, with IDV being least bound
(60%). Increasing AAG had no eVect on ZDV
eYcacy, consistent with lack of ZDV-AAG
binding. Table w1 (on website) describes the
plasma protein binding characteristics of cur-
rently available antiretrovirals.
Distribution mechanisms of antiretroviral
agents into other sanctuary sites
More is known about antiretroviral drug
disposition across the placenta, into urine, and
across the blood-brain barrier than about drug
disposition into semen. It is likely that the
mechanisms regulating antiretroviral drug dis-
position and accumulation in the male genital
tract are similar to the mechanisms described
here.
PLACENTA
Maternal to fetal transport of ZDV and
lamivudine (3TC) were studied in two separate
laboratories using ex vivo human term placen-
tas. Transfer was non-saturable with no accu-
mulation on the fetal side. Therefore, diVusion
is one mechanism by which ZDV and 3TC
cross the placenta. Because addition of nucle-
oside transport inhibitors did not alter the
transfer of ZDV, this transport system does not
appear to be involved with the placental dispo-
sition of ZDV. However, active transport, by
mechanisms other than the nucleoside trans-
port system, could not be excluded.31 32
KIDNEY
GriYths et al33 34 were the first to study antiret-
roviral renal clearance. They found ZDV clear-
ance was greater than the glomerular filtration
rate, indicative of tubular secretion of ZDV.
Using rat membrane vesicles, they showed that
ZDV uses both the basolateral organic anion
and the brush border organic cation transport
systems, and suggested the azido moiety of
ZDV might result in a pseudo-zwitterion capa-
ble of using both transport systems.
Bendayan et al35 studied tubular secretion of
ZDV in cultured renal epithelium. The flux of
ZDV was greater than that of diVusion limited
mannitol, indicative of active transport. Several
organic bases (cimetidine, trimethoprim, qui-
nine, and quinidine) limit ZDV flux, further
evidence that ZDV uses the organic cation
transport system. Again, the azido group was
presumed to be the component allowing ZDV
to act as an organic base.
Aiba et al36 and Chatton et al37 infused rats
with ZDV, with and without co-administration
of either probenecid (an anionic drug) or
cimetidine (a cationic drug). Both drugs inhibit
ZDV renal secretion. Rats given p-amino-
hippurate or imipramine, putative organic
anion and organic cation transport inhibitors,
respectively, also demonstrated reduced ZDV
renal secretion. This confirms renal secretion
of ZDV by organic anion transporters and
organic cation transporters.
CENTRAL NERVOUS SYSTEM (CNS)
Protease inhibitors
Protease inhibitors are substrates of
p-glycoprotein (P-gp),38 39 a 170 kDa trans-
membrane ATP dependent eZux pump found
in brain capillary endothelial cells and in the
epithelia of testis and prostate.40 41 At the
blood-brain barrier, P-gp pumps PIs out of the
CNS, preventing drug accumulation.42 43 Other
tissues that contain P-gp (adrenal cortex,
kidneys, intestines, liver, pancreas, placenta,
and haematological cells—including CD4+
and CD8+ cells, monocytes, and macro-
phages) also have reduced penetration by pro-
tease inhibitors.38 39
Using P-gp expressing Caco-2 monolayers,
Lee et al39 showed protease inhibitors bind to
P-gp and compete for P-gp mediated eZux.
For example, RTV, SQV, and IDV compete
with iodoarylazidoprazosin (a photoaYnity
substrate of P-gp) and inhibit transport of
cyclosporin A (a substrate of p-glycoprotein
transport). Other experiments demonstrate
P-gp mediates transport of IDV, NFV, SQV,
RTV, and APV across Caco-2 cells unidirec-
tionally.42 43 In fact, the basolateral to apical flux
is 2–23 fold higher than apical to basolateral
flux for APV, IDV, RTV, and SQV. Other
evidence of P-gp involvement in PI transport
includes prevention of basolateral to apical flux
by the P-gp inhibitor GF-120918.43
Kim et al42 and Polli et al,43 working
separately, used mice to study whether P-gp
prevented PI accumulation within the central
nervous system. In mice, both mdr-1a and
mdr-1b genes express P-gp. Kim used a single
knockout (mdr-1a −/−) mouse strain; Polli
used a double knockout (mdr-1a −/− and
mdr-1b −/−) mouse strain and genetically nor-
mal mice pretreated with GF-120918. The
amount of IDV, NFV, and SQV increased in
the CNS of single knockout mice, compared
with control mice. The double knockout mice
and normal mice pretreated with GF-120918
had increased CNS concentrations of APV
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when compared with normal mice without
pretreatment. These mice studies confirm in
vivo eZux of PIs from the CNS by P-pg.
Reverse transcriptase inhibitors
The CNS concentration of nucleoside reverse
transcriptase inhibitors (NRTIs) is less than
their concomitant blood plasma concentration.
This suggests active eZux and/or sequestration
of NRTIs in blood plasma. It was shown that
the transport of ZDV across the rabbit
blood-brain barrier is asymmetric, with eZux
greater than influx and no evidence of seques-
tration in plasma.44–46 This diVers from disposi-
tion mechanisms of thymidine, which enters
and accumulates in the CNS via multiple
nucleoside transporters.44 45 However, ribonu-
cleosides or deoxyribonucleosides modified in
the 2', 3', or 5' position will not be transported
by the sodium dependent nucleoside uptake
systems found in the CNS.47 The general con-
clusion, after in vitro and in vivo experimenta-
tion, is that nucleosides enter the CNS by dif-
fusion where they are pumped out by organic
acid transporters.
Evidence of entry into the CNS by diVusion
is based on the [Drug]CNS:[Drug]Plasma ratios of
ddI and ZDV, which are best explained by dif-
ferences in their diVusion rates. The only diVu-
sion related diVerence between the two drugs is
their partition coeYcient. The more lipid solu-
ble ZDV has a higher [Drug]CNS:[Drug]Plasma
ratio than the less lipid soluble ddI, as would be
predicted by Frick’s law.
Evidence of active eZux of reverse tran-
scriptase inhibitors is based on saturation and
inhibition studies. Takasawa et al48 49 first dem-
onstrated that the eZux of ZDV and ddI was
saturable, indicating mediated transport. This,
as well as evidence that this eZux transfers
ZDV and ddI against their concentration
gradients, signifies active transport. There is in
vivo evidence that this transport occurs via an
organic anion transport system.48 49 Probenecid
or p-aminohippurate increases ZDV and ddI
[Drug]CNS and [Drug]CNS:[Drug]Plasma in rats and
rabbits.48 Thymidine co-administration did not
aVect the eZux of ZDV or ddI, again ruling out
similar transport mechanisms for the drugs and
this intrinsic nucleoside.
EZux of NRTIs from the CNS by P-gp
needs to be studied as there are currently no
data to suggest ZDV and other nucleosides are
substrates of this transport system.




Henry et al first described ZDV concentrations
in semen in 1988, while studying six patients
receiving ZDV monotherapy.25 They calculated
[ZDV]Semen:[ZDV]Plasma ratios approximately 1
hour and 3–4 hours post-drug ingestion and
these ranged from 1.3–20.4 and 2.3–16.8,
respectively. They found the ratios, although
variable at both time points, suggested that
ZDV, and perhaps other antiretrovirals, can
accumulate within semen. Pereira et al50 deter-
mined ZDV and 3TC concentrations in the
blood and seminal plasma of nine men
commencing therapy. In this study, 70 paired
seminal and blood plasma samples were
obtained. The median [ZDV]Semen:[ZDV]Plasma
ratio was 5.9, with 81% of the samples having
higher [ZDV]Semen than [ZDV]Plasma.
More recently Anderson et al,51 using a timed
dose administration and timed single sample
strategy, were able to create an area under the
concentration time curve (AUC) for ZDV in
semen and blood plasma. They found that
zidovudine and zidovudine-gluconeride con-
centrations were uniformly higher in semen
than in plasma at all time points except at 1
hour after the dose. Finally they found the
[ZDV]semen AUC:[ZDV] plasma AUC was 3.31 which is
consistent with previous findings.
Lamivudine (3TC)
In the same study by Pereira et al,50 the median
[3TC]Semen:[3TC]Plasma ratio was 5.9, with 81.4%
of the seminal plasma samples having a higher
[3TC]Semen than concomitant [3TC]Plasma. Two
other studies also suggest accumulation of
3TC in semen. One study looked at eight
patients and found [3TC]Semen were approxi-
mately five times [3TC]Plasma. Interestingly, the
ratios changed over time; ratios at 2–4 hours
and 8–12 hours post drug ingestion were 4.6
(range 2.5–6.4) and 8.7 (4.0–16.3), respec-
tively.52 In a separate study involving eight
patients, median [3TC]Semen was 1062 ng/ml
compared with a median [3TC]Plasma of 329
ng/ml.53
Stavudine (d4T)
Data on [d4T]Semen are confined to two small
studies. The first study involved 10 patients
receiving d4T. In some patients, d4T was
undetectable in seminal and blood plasma
samples. However, when detected, [d4T]Semen
was similar in magnitude to [d4T]Plasma. When
detectable, the median [d4T]Semen:[d4T]Plasma
ratios at 0–2 hours, 2–4 hours, and 8–12 hours
were 0.46 (range 0.19–0.73), 2.7 (0.47–4.80),
and 3.5 (1.0–6.0 ), respectively.52 The second
study, in eight patients showed that [d4T]Semen
(median 104 ng/ml) was again similar to
[d4T]Plasma (78 ng/ml).
53
At the time of writing there were no data on
the concentrations of didanosine (ddI), zalcit-





There has been one published paper describ-
ing nevirapine penetration into the seminal
plasma of 12 HIV-1 infected men receiving
NVP containing regimens. It was found that
NVP penetrates into semen well, with
[NVP]Semen:[NVP]Plasma ratios consistently be-
tween 0.6–1. Interestingly, these ratios were not
dependent on the time post drug ingestion.
The authors of the report estimated that the
free [NVP]Semen should remain greater than 40
times the EC90 for wild type HIV-1 at all time
points. (The EC90 is the eVective concentration
of drug required to inhibit viral replication by
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90% in an vitro cell culture assay. This figure
may, or may not, be corrected for drug/plasma
protein binding interactions (see below)). In
this study, 10/12 patients had seminal viral
loads below the limit of detection at the time of
the study.52
Efavirenz (EFV)
There have been no published studies on
[EFV]semen; however, recently Kim et al
54 have
presented data suggesting that EFV also
achieves therapeutic concentrations in semen.
In this study they were able to obtain semen
samples over the 24 hour dosing period and
found that 24 hour [EFV]semen:[EFV] plasma ratios
more predictive than individual semen:plasma
ratios.
Similarly, we have data on 19 HIV-1 positive
individuals who commenced EFV containing
regimens. All patients in this study had seminal
plasma viral load suppressed by 24 weeks and
[EFV]semen at 12 and 24 hours post drug inges-
tion were approximately 10% of [EFV]plasma
(unpublished data).
Data on delavirdine [Drug]Semen were unavail-
able at the time of writing.
PROTEASE INHIBITORS (PIS)
Indinavir (IDV)
Two recent studies have investigated IDV pen-
etration into semen. Taylor et al55 reported that
[IDV]Semen was high and similar to concurrent
[IDV]Plasma. The median [IDV]Semen:[IDV]Plasma
ratios 0–3, 3–6, and 6–9 hours post drug inges-
tion were 0.62, 0.8, and 1.4, respectively.
Trough [IDV]Semen was above the protein
corrected EC95 for IDV in blood plasma at all
times. All seven patients in this study reached
an undetectable viral load in blood and seminal
plasma.
A second study by Van Praag et al56 has
recently been published. In this study low dose
RTV (100 mg) was added to 13 patients
already taking IDV containing regimens.
Semen and CSF samples were available at
baseline and after addition of RTV in six of
these patients. Interestingly they found that
addition of RTV increased [IDV]Semen by 8.2
times (95% confidence interval (CI) 5.2–11.6)
and [IDV]CSF by 2.4 times (95% CI 1.8–3.9).
They concluded that the increases in [IDV]plasma
alone were not suYcient to explain the large
increases in [IDV]Semen and [IDV]CSF and postu-
lated modulation of P-gp as a potential mech-
anism.
Ritonavir (RTV) and saquinavir (SQV)
[RTV]Semen has only been determined in seven
patients receiving RTV, SQV, and stavudine.
Median [Drug] Semen:[Drug]Plasma ratios were
less than 0.05 at 2 and 12 hours post adminis-
tration. [RTV]Semen fell below the protein
corrected EC95 in all seven patients. Median
[SQV]Semen:[SQV]Plasma ratios were also less than
0.05 at 2 and 12 hours post administration.
Despite high [SQV]Plasma, [SQV]Semen was unde-
tectable (less than 25 ng/ml) in 7/12 samples.
In this study, viral load became undetectable in
both seminal and blood plasma. However,
because of the complex regimen, it is impossi-
ble to make a correlation between [Drug]Semen
and viral suppression.57
Saquinavir (SQV) and nelfinavir (NFV)
A study by Reijers et al53 measured [SQV]Semen
and [NLF]Semen in eight patients taking part in
the four drug ADAM study (NFV, SQV, d4T,
and 3TC). SQV was only detected in 3/8
semen samples at low concentrations. NFV
could not be detected in any of the seminal
plasma samples.
Amprenavir (APV)
Pereira et al58 determined [APV]Semen in 31 men.
In this study, median [APV]Semen was 269 ng/ml
with an interquartile range (IQR) of 73–929
ng/ml. The concomitant median [APV]Plasma
was 1210 ng/ml with an IQR of 326–4696
ng/ml. Time post drug ingestion was approxi-
mately 6 hours. Seminal viral load was
measured in all samples obtained. [APV]Semen
were above the protein corrected EC95 for APV
in blood plasma in some but not all patients.
Seminal viral load was less than 400 copies per
ml in 14/19 and 7/9 men receiving APV mono-
therapy and APV/ZDV/3TC, respectively.
Factors limiting interpretation of seminal
plasma drug concentrations





Currently, drug concentrations in semen are
reported in a variety of ways. These include
[Drug]Semen:[Drug]Plasma ratios and simply
[Drug]Semen. In either case only the total
[Drug]Semen, not free [Drug]Semen has been
measured. As described above, protein binding
can aVect the amount of drug available for
antiretroviral activity. This needs to be taken
into account when interpreting data. There are
currently no analyses of seminal antiretroviral
protein binding or free [Drug]Semen.
In blood plasma, free drug concentration can
be inferred from protein corrected EC50 and
EC95. For example, Molla et al
59 added 50%
human blood plasma to cell cultures and
determined EC50 values for PIs both before and
after the addition of human blood plasma.
Unfortunately, seminal plasma is toxic to
cultured cells and similar experiments have not
been performed with seminal plasma.
Some authorities believe that for adequate
free drug concentrations to be available in vivo,
drug concentrations should be targeted above
“protein corrected EC95s” in all compartments.
However, establishing the minimum drug con-
centrations in plasma remains an area of
controversy. The minimum concentrations in
extravascular compartments are even less clear.
WHEN TO MEASURE
Most researchers express drug deposition into
semen as a ratio, [Drug]Semen:[Drug]Plasma. Use of
ratios can be misleading. They rely on single
time point measurements, which give static
observations on the dynamic processes of drug
accumulation and drug elimination. Ratios also
compare drug concentrations between com-
partments that probably have diVerent rates of
accumulation and elimination. Table w1 (see
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website) lists the plasma half life of various
antiretroviral drugs. This can lead to ratios that
vary with time. These issues regarding the use
of ratios lead to the question of when to sample
blood and semen to get a realistic idea of the
pharmacokinetics of antiretrovirals in the male
genital tract.
Several groups report [Drug]CSF:[Drug]Plasma
ratios vary with time post dose. For example,
ZDV is cleared rapidly from blood plasma and
penetrates slowly into CSF. Thus, over time,
ZDV blood plasma concentrations decrease
and CSF concentrations increase, resulting in
[Drug]CSF:[Drug]Plasma ratios that increase with
time post-dose.60 Lamivudine, d4T, and IDV
also have [Drug]CSF:[Drug]Plasma ratios that
are time dependent.61 62 Interestingly,
[NVP]Semen:[NVP]Plasma ratios are relatively con-
stant over time.52 Ideally a ratio of the semen
AUC to plasma AUC would give the best indi-
cation of overall drug exposure. However,
obtaining AUC measurements for semen is
technically and practically very diYcult.
STATISTICAL PARAMETERS TO ESTIMATE GENITAL
TRACT EXPOSURE
To make an informed interpretation of
[Drug]compartment:[Drug]Plasma ratios, the time post
drug ingestion should be stated. If possible, the
time between sampling the two compartments
should be as close as possible. For the male
genital tract, time since last ejaculation may
also be relevant. Recently, several groups have
attempted to estimate mathematically viral
exposure to various antiretrovirals in various
compartments. For example, population based
pharmacokinetic modelling, using a NONMEM
program instead of isolated ratios, has recently
been applied to the study of antiretroviral
disposition into CSF. It is probable that similar
population modelling has applications in the
field of studying drug penetration into the male
genital tract.63
INTRACELLULAR DRUG CONCENTRATIONS
The study of drug penetration into sanctuary
sites is in its infancy. So far, researchers have
only reported [Drug]Extracellular in semen, not
[Drug]Intracellular. However, because current
antiretrovirals act intracellularly [Drug]Intracellular
is more meaningful. Further, because NRTIs
require intracellular triphosphorylation for
activity, [NRTI-triphosphate]Intracellular concen-
trations and not [NRTI]Intracellular are the more
relevant measurements.64 Since several studies
have demonstrated a poor correlation between
plasma concentrations of nucleoside analogues
and intracellular concentrations, estimates of
[Drug]Intracellular based on [Drug]Extracellular may be
misleading.
Conclusions
Given that drug penetration into semen
appears to be drug specific, it is surprising that
most of the studies looking at the eYcacy of
HAART on genital tract shedding have shown
a variety of regimens to be eVective. There may
be several reasons for this. In most of the stud-
ies, combinations of drugs have been used. In
addition, most studies have included at least
one or two drugs shown to reach therapeutic
concentrations in semen. It is interesting to
note that studies of monotherapy regimens
failed to suppress seminal viral load in a
substantial proportion of cases.65 66 Currently,
it is unknown what drugs and what concentra-
tions are required to suppress genital tract
viraemia.
The study of drug disposition into anatomi-
cal sanctuary sites is becoming increasingly
important. The male genital tract is of particu-
lar relevance as semen represents the major
vehicle for sexual transmission. Early reports
suggest that drug penetration into semen is
drug specific and may depend on a variety of
drug specific physiochemical properties and
host specific biological mechanisms. More
studies are needed to determine how antiretro-
virals in seminal plasma aVect clinical outcome
or the sexual transmission of HIV-1.
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